Silo Pharma Collaborates with Veloxity for PTSD Treatment Drug Research

Summary

Silo Pharma Inc. has partnered with Veloxity Labs to conduct bioanalytical studies for its nasal PTSD treatment drug SPC-15 as part of the IND initiation process. This collaboration supports ongoing GLP-compliant toxicology studies, with plans to initiate FDA IND processes in 2025 and advance to Phase I clinical trials. CEO Eric Weisblum highlighted Veloxity Labs’ crucial role in providing necessary clinical progression data.Reuters

Impact Analysis

Silo Pharma’s partnership with Veloxity Labs for SPC-15 research is a pivotal product milestone that enhances the company’s ability to progress towards clinical trials, specifically Phase I. First-order effects include the potential for increased investor confidence and future revenue growth by advancing SPC-15 closer to market readiness in the multi-billion dollar PTSD market. Additionally, the collaboration with Veloxity Labs and ongoing studies with Frontage Laboratories Reuters+ 3 underscore Silo’s strategic focus on fulfilling FDA requirements and strengthening its drug development capabilities. Second-order effects may involve increased attention from competitors and potential partnerships within the biopharmaceutical industry, as successful development of SPC-15 could position Silo Pharma as a leader in PTSD treatment. Investment opportunities might involve considering long positions in Silo Pharma’s stock, anticipating positive developments and strategic value from the drug’s clinical progress.Reuters